DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* GENTICEL *


 

2001 - Midi-Pyrénées
Labège
(near Toulouse)
www.genticel.com

 

Discovery, Immunology
Key words: Therapeutic vaccines, HPV, Cancer, Viral and bacterial infections, ProCervix
Mission: to develop immuno-therapeutic products for the treatment of infection, neoplasia and cervical cancer, caused by Human Papillomavirus (HPV)
Clients: Prescribers
business@genticel.com

Age: 15 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Timmerman (Ben) [founder, born 1959, Ph.D. Molecular Genetics, MBA, ex-Novartis Agro, Procordia]
Sc.Dir.-CSO: Bissery (Marie-Christine) [Ph.D., Pharm.D., ex-Sanofi–Aventis, Rhône-Poulenc]
Fin.Dir.-CFO: Koch (Martin) [Eng., MBA, ex-Eli Lilly, Cap Gemini, Elan, Zeneus, Cephalon]
BusDev:
Financers (Hist.): Institut Pasteur, FAM-Midi-Pyrénées, Edmond de Rothschild Investment Partners, IRDI, Amundi Private Equity Funds, InnoBio, FSI
Note : from inception to February 2010, the company name has been BT Pharma (BT for Benedikt Timmerman, Founder)

Turnover (M€) : 0.36 (2006)
Total funding (M€) : 24.0
Last funding (M€) : 13.1
Focus : Vaccines
Position : Clinical
Company confirm : 2-May-2011

 

History
DATEMILESTONETYPETIME
2012 .10 Clinical trial (phase Ib) for Procervix (redesigned) aimed at preventing cervical cancer in patients already infected by HPV (positive results on primary objective, safety and local tolerance, and secondary objective, antigen-specific cellular immunity) CLIN [11 years]
2011 .10 Clinical trial (phase I) for Procervix (redesigned) aimed at preventing cervical cancer in patients already infected by HPV (recruitment completed) CLIN [10 years]
2010 .07 Clinical trial (phase I) for Procervix (redesigned) aimed at preventing cervical cancer in patients already infected by HPV (beginning) CLIN [8 years]
2010 .03 3rd round-financing : 13.1 M€, led by AGF Private Equity, with 3 new investors, IRDI (Institut Régional de Développement Industriel), Amundi Private Equity Funds and InnoBio fund, managed by CDC Entreprises, and previous investors, including Edmond de Rothschild Investment Partners (EdRIP) RFINC [8 years]
2010 .02 Company name change from BT Pharma to Genticel INFO [8 years]
2008 .09 2nd round-financing : 2.8 M€ mainly by Edmond de Rothschild Investment Partners, followed by Fonds d'Amorçage Midi-Pyrénées RFINB [6 years]
2007 .09 Clinical trial (phase I) for Procervix, HPV vaccine (beginning) CLIN [5 years]
2007 .05 1st round-financing : 1.3 M€, mainly by Institut Pasteur and an undisclosed private investor RFINA [5 years]
2001 .10 Company founded by Benedikt Timmerman, as a spin-off from Institut Pasteur (Paris) ORGF [0 year]

Actualisation / Updating: 27-Sep-2011

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende